New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2013
16:04 EDTARRYArray BioPharma to initiate Phase 3 trial evaluating MEK162
Array BioPharma announced that it will initiate a global Phase 3 clinical trial in patients with recurrent low-grade serous ovarian cancer during the summer of 2013. The study, called MILO, will evaluate the efficacy and safety of MEK162 compared to standard chemotherapy treatments and is designed for worldwide regulatory submissions, including with the U.S. Food and Drug Administration and the European Medicines Agency. Array invented MEK162 and licensed worldwide rights to develop and commercialize the drug to Novartis in April 2010. The MILO study follows a recent announcement by Novartis detailing plans to initiate Phase 3 trials of MEK162 in both NRAS- and BRAF-mutant melanoma and will be covered as part of the Novartis/Array co-development agreement under which costs are capped annually and in total for Array.
News For ARRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2015
07:43 EDTARRYJefferies to hold a conference
Subscribe for More Information
November 16, 2015
09:19 EDTARRYOn The Fly: Pre-market Movers
HIGHER: Nexvet Biopharma (NVET), up 16.8% after NV-01 study meets primary endpoint... Protalix BioTherapeutics (PLX), up 4.8% after announcing that it will conduct a Phase III clinical trial for PRX-102... Array Biopharma (ARRY), up 4.3% after announcing a commercialization collaboration with Pierre Fabre... Perrigo (PRGO), up 2.1% after being upgraded to Buy from Neutral at UBS. DOWN AFTER EARNINGS: Dillard's (DDS), down 11.7% after reporting quarterly results. ALSO LOWER: Clovis Oncology (CLVS), down 71.3% after the FDA requested additional clinical data for rociletinib... KaloBios Pharmaceuticals (KBIO), down 48.9% after announcing that it will wind down its operations... Starwood Hotels (HOT), down 6.3% after announcing that Marriott (MAR) will acquire the company... Marriott is down 2.4%... Five Below (FIVE), down 3.1% after being downgraded to Hold from Buy at Deutsche Bank.
08:19 EDTARRYArray BioPharma to hold a conference call
Management announces Array BioPharma and Pierre Fabre will collaborate to globally develop and commercialize Array's two novel oncology products, Binimetinib and Encorafenib, on a conference call to be held on November 16 at 9 am. Webcast Link
07:36 EDTARRYArray BioPharma and Pierre Fabre announce commercialization collaboration
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use